Illumina Files Additional Patent Infringement Suit Against BGI in the U.S.
February 27 2020 - 4:05PM
Business Wire
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed
a patent infringement suit relating to BGI’s “CoolMPS” sequencing
products. The complaint was filed against BGI Genomics Co., Ltd.,
BGI Americas Corp., MGI Tech Co., Ltd., MGI Americas, Inc. and
Complete Genomics Inc. in the United States District Court for the
Northern District of California alleging infringement of three
patents: US Patent Nos. 7,541,444; 7,771,973; and 10,480,025. The
complaint seeks, among other things, damages, injunctive relief and
attorney fees. The patents cover Illumina’s proprietary
sequencing-by-synthesis chemistry.
“BGI has brazenly copied Illumina’s proprietary sequencing
chemistry. Illumina’s patent portfolio reflects the incredible
innovation of Illumina’s employees and the investment of hundreds
of millions of dollars that Illumina spends annually on research
and development,” said Charles Dadswell, SVP and General Counsel
for Illumina. “We will continue to monitor and defend our
intellectual property by appropriate enforcement when our patents
are infringed.”
Related patent suits are pending in Denmark, Germany, Sweden,
Switzerland, Turkey, the UK and the U.S. Counterparts to these
newly asserted patents have been upheld by the U.S. Patent Trial
and Appeal Board and the European Patent Office over challenges
filed by BGI, Complete Genomics and others.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200227005919/en/
Illumina, Inc. Investors: Jacquie
Ross, CFA +1-858-255-5243 ir@illumina.com
Media – U.S.: Tina Amirkiai 858-882-6822 pr@illumina.com or
Media – Europe, Middle East and Africa: Karen Birmingham +44(0)
7500105665 kbirmingham@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024